Filtered By:
Drug: Fortamet
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 8614 results found since Jan 2013.
The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis
CONCLUSIONS: Due to the dearth of related research and the high heterogeneity of the Randomized Clinical Trials (RCTs) included in other studies, the present systematic review could not establish any differences between metformin and myo-inositol concerning the hormonal profile and the ovarian function. However, the findings indicated that myo-inositol could improve fertility outcomes by modulating hyperandrogenism. Randomized trials are required to understand the mechanistic actions of myo-inositol in comparison with those of metformin regarding oocyte and embryo quality, fertilization, pregnancy, and live birth rates.PMI...
Source: European Review for Medical and Pharmacological Sciences - April 20, 2021 Category: Drugs & Pharmacology Authors: M Azizi Kutenaei S Hosseini Teshnizi P Ghaemmaghami F Eini N Roozbeh Source Type: research
Metformin for diabetes prevention: Update of the evidence base
Curr Med Res Opin. 2021 Jul 20:1. doi: 10.1080/03007995.2021.1955667. Online ahead of print.ABSTRACTWe have conducted a narrative review based on a structures search strategy, focussing on the effects of metformin on the progression of non-diabetic hyperglycaemia to clinical type 2 diabetes mellitus. The principal trials that demonstrated a significantly lower incidence of diabetes in at-risk populations randomised to metformin (mostly with impaired glucose tolerance [IGT]) were published mainly from 1999 to 2012. Metformin reduced the 3-year risk of diabetes by -31% in the randomised phase of the Diabetes Prevention Progr...
Source: Current Medical Research and Opinion - July 20, 2021 Category: Research Authors: Ulrike Hostalek Ian Campbell Source Type: research
Could the use of butyric acid have a positive effect on microbiota and treatment of type 2 diabetes?
CONCLUSIONS: T2DM is a widespread chronic disease. Understanding role of microbiota in type 2 diabetes and the mechanisms connecting T2DM and alterations in gut microbiota could be the key to improved treatment of T2DM.PMID:34286509 | DOI:10.26355/eurrev_202107_26250
Source: European Review for Medical and Pharmacological Sciences - July 21, 2021 Category: Drugs & Pharmacology Authors: E Stachowska M Wi śniewska A Dzie życ A Bohatyrewicz Source Type: research
Metformin for diabetes prevention: Update of the evidence base
Curr Med Res Opin. 2021 Jul 20:1. doi: 10.1080/03007995.2021.1955667. Online ahead of print.ABSTRACTWe have conducted a narrative review based on a structures search strategy, focussing on the effects of metformin on the progression of non-diabetic hyperglycaemia to clinical type 2 diabetes mellitus. The principal trials that demonstrated a significantly lower incidence of diabetes in at-risk populations randomised to metformin (mostly with impaired glucose tolerance [IGT]) were published mainly from 1999 to 2012. Metformin reduced the 3-year risk of diabetes by -31% in the randomised phase of the Diabetes Prevention Progr...
Source: Current Medical Research and Opinion - July 20, 2021 Category: Research Authors: Ulrike Hostalek Ian Campbell Source Type: research
Could the use of butyric acid have a positive effect on microbiota and treatment of type 2 diabetes?
CONCLUSIONS: T2DM is a widespread chronic disease. Understanding role of microbiota in type 2 diabetes and the mechanisms connecting T2DM and alterations in gut microbiota could be the key to improved treatment of T2DM.PMID:34286509 | DOI:10.26355/eurrev_202107_26250
Source: European Review for Medical and Pharmacological Sciences - July 21, 2021 Category: Drugs & Pharmacology Authors: E Stachowska M Wi śniewska A Dzie życ A Bohatyrewicz Source Type: research
Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials
CONCLUSIONS: Compared with metformin, the suitable supplemental dosage of myo-ins may be helpful in lowering levels of TG and avoiding adverse events (AEs).PMID:35363325 | DOI:10.26355/eurrev_202203_28322
Source: European Review for Medical and Pharmacological Sciences - April 1, 2022 Category: Drugs & Pharmacology Authors: J-Q Zhang C Xing B He Source Type: research
